Alivus Life Sciences’ board has approved the share purchase agreement to acquire 76% stake in IQGEN-X Pharma for an aggregate consideration of approximately Rs 9.12 crore subject to adjustment as per Share purchase agreement.
IQGEN-X Pharma provides a wider spectrum for the company to offer a complete end-to-end solution to its customers in both API and CDMO space. The Board of Directors of the company at its meeting held on August 18, 2026, approved the same.
Alivus Life Sciences (formerly Glenmark Life Sciences) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes.
